Clinical Trial Update: Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Blood Stem Cell Transplantation [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial update evaluating tacrolimus, sirolimus, and methotrexate as prophylaxis for graft-versus-host disease after blood stem cell tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Hematologic Malignancies

Drugs mentioned

• METHOTREXATE (METHOTREXATE)
• Sirolimus (Sirolimus)
• Tacrolimus (Tacrolimus)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Graft Versus Host Disease, Hematologic Malignancies | Phase 2 | Status: COMPLETED